Translational Development Acquisition Corp. (TDAC) shareholders
TDACNasdaqBlank ChecksFiscal year ends December 31Also trades as TDACU, TDACW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$10.87+0.01 (+0.09%)
Close on Nov 17, 2026Market cap $209.89MP/E –Yield –
Ownership
Who owns Translational Development Acquisition's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Robert R. Bellick Joint filing with Wolverine Asset Management LLC (9.03%), Wolverine Trading Partners, Inc. (9.03%) and 2 more | 1,557,134 | 9.03% | 13G (passive) amendment | Sep 30, 2025 |
| Wolverine Trading Partners, Inc. Joint filing with Wolverine Asset Management LLC (7.85%), Wolverine Holdings, L.P. (7.85%) and 2 more | 1,354,691 | 7.85% | 13G (passive) amendment | Jun 30, 2025 |
| Magnetar Financial LLC Joint filing with Magnetar Capital Partners LP (7.53%), Supernova Management LLC (7.53%) and 1 more | 1,300,000 | 7.53% | 13G (passive) | Dec 31, 2024 |
| Linden Advisors LP Joint filing with Siu Min Wong (6.70%), Linden Capital L.P. (6.40%) and 1 more | 1,150,000 | 6.70% | 13G (passive) amendment | Jun 30, 2026 |
| AQR Capital Management Holdings, LLC Joint filing with AQR Capital Management, LLC (6.38%), AQR Arbitrage, LLC (6.38%) | 1,099,989 | 6.38% | 13G (passive) amendment | Mar 31, 2025 |
| The Goldman Sachs Group, Inc. Joint filing with Goldman Sachs & Co. LLC (7.20%) | 1,056,879 | 7.20% | 13G (passive) amendment | Jun 30, 2026 |
| Bank of Montreal Joint filing with Bank Of Montreal Holding Inc. (5.79%), Bmo Nesbitt Burns Inc. (5.79%) | 1,000,000 | 5.79% | 13G (passive) | Mar 31, 2025 |
| Meteora Capital, LLC | 919,000 | 6.27% | 13G (passive) | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael B. Hoffman | Chairman and CEO, Director | – | – | May 29, 2026 |
| Avanindra Das | Chief Financial Officer | – | – | Dec 20, 2024 |
| Christopher Kenneth Jarratt | Director | – | – | Jan 6, 2025 |
| E. Premkumar Reddy | Director | – | – | Dec 20, 2024 |
| Curtis T. Keith | Director | – | – | Dec 20, 2024 |
| Matthew Kestenbaum | Director | – | – | Dec 20, 2024 |
| Partners LLC TDAC | 10% owner | – | – | Dec 20, 2024 |
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+37.8%
From 0M shares
Short volume, 20 days
3.5%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Translational Development Acquisition's stock actually held short. Settlement fails (shares not delivered on time) peaked at 774 shares on Aug 25, 2026 over the last 90 days.
See a number that looks wrong?